Detection of minimal residual disease in adult acute myeloid leukemia via CD25

**CURRENT STATUS:** UNDER REVIEW

**BMC Cancer**

Wei Wang  
Peking University International Hospital

Yan Li  
Peking University International Hospital

Lan Ma  
Peking University International Hospital

Wen-Qing Hu  
Peking University International Hospital

Bin Jiang  
jiangbin@pkuih.edu.cn  
Peking University International Hospital  
*Corresponding Author*  
*ORCiD:* 0000-0003-2473-2129

**DOI:** 10.21203/rs.2.13678/v2

**SUBJECT AREAS**  
Oncology  
Cancer Biology

**KEYWORDS**  
CD25; acute myeloid leukemia; minimal residual disease; flow cytometry
Abstract

Background We detected the expression of CD25 in patients with acute myeloid leukemia (AML) to value whether CD25 could be a promising marker for minimal residual disease (MRD). Methods Two hundred and twenty bone marrow (BM) specimens from 98 adult patients with AML after chemotherapy were detected using flow cytometry. The expression of CD25 was compared between MRD positive and negative subgroups. Results About 38% of patients with MRD were positive for CD25. The mean percentage of CD25-positive cell subpopulation was 58.68% relative to the whole MRD cluster (0.05%-100%). The mean fluorescence index ratio (MFIR) of CD25 in these cell subpopulations was approximately 13-fold greater than that in normal myeloblasts. The detection sensitivity of CD25 was as high as $10^{-4}$. CD25 was also expressed on non-leukemic stem cells that were positive for CD34 and CD38. Conclusion CD25, as assessed by flow cytometry, is a promising marker for MRD in patients with AML.

BACKGROUND

In acute myeloid leukemia (AML), the presence of minimal residual disease (MRD), in which the number of leukemic cells is lower than the detection threshold of morphology, is an independent prognostic parameter of relapse and survival [1-6]. Flow cytometry (FC), molecular techniques, and cytogenetic analysis are three prominent technologies for detecting MRD[1,4,7-10]. Generally, there are two approaches for MRD detection by FC: detection of cells with leukemia-associated immunophenotypes (LAIPs), which differ from normal hematopoietic cells [11-13]; detection of different from normal (DfN) patterns [10]. These approaches can also
be combined as a “LAIP-based DfN approach” [14]. With the mounting number of LAIP [1,3] and the application of multiparameter FC, the detection sensitivities of FC can be as high as 1:103 to 1:106 in BM samples [10, 14, 15]. All these methods are based on antigens with abnormal expression. To reduce the false detection of MRD-negative ratios and expand the application scope, novel MRD markers need to be developed.

CD25 (interleukin-2 receptor) is expressed in 10%-20% of patients with AML [15,16]. This marker is correlated with FLT3-ITD, DNMT3A, and NPM1 mutations [16,17]. It has also been proven to be an independent, unfavorable prognostic parameter in AML [16-18]. More recently, CD25 has been detected in leukemic stem cells (LSCs) in patients with myelodysplastic syndrome [19]. Here, we used CD25 as a novel marker to detect MRD in patients with AML.

METHODS

Patients
The BM samples were obtained with informed consent. The study was approved by the Ethics Committee of the Peking University International Hospital and was in compliance with the guidelines of the Helsinki Declaration of 2008. A total of 220 longitudinal BM specimens from 98 adult AML patients (55 males and 43 females) were collected after chemotherapy from Peking University International Hospital between June 2017 and June 2019. Among the samples, 165 BM samples from 43 patients were collected at different time points after chemotherapy.

Flow cytometry
Fluorescent mouse anti-human monoclonal antibodies (mAbs) against the following markers were used: CD2, CD5, CD7, CD11b, CD13, CD14, CD15, CD19, CD25, CD33,
CD34, CD36, CD38, CD41, CD45, CD56, CD61, CD64, CD71, CD117, CD123, CD235a, and HLA-DR (from BD Biosciences and Beckman Coulter). The MRD detection panels are listed in Additional file 1.

BM samples were collected in heparin anticoagulant tubes. A total of $5 \times 10^5$ white blood cells/tube were stained and detected within 12 hours after procurement. Data were acquired and analyzed using a BD FACSCalibur flow cytometer and Cell Quest software (from BD Biosciences).

MRD as determined by FC was defined as reported [14]. CD25 expression was calculated as the MFIR as described previously [20]. In MRD-negative BM samples, normal myeloblasts are positive for CD34, CD117, and CD45. Based on the expression profile of CD25, the MRD-positive BM samples were separated into two subgroups. If there was a CD25-positive subpopulation, the MFIR of CD25 applied only to this subpopulation instead of to the whole MRD cluster. In addition, the positive percentage of cells positive for CD25 in the MRD cluster was recorded. If the whole MRD cluster was positive for CD25, then the MFIR of CD25 applied to the whole cellular cluster.

**PCR assay**

All BM samples were analyzed by PCR. Five-milliliter BM samples were collected in in EDTA anticoagulant tubes. The PCR assay was performed based on previous reports [4,10,14] Fusion genes (PML-RARA, CBFB-MYH11, RUNX1-RUNX1T1, BCR-ABL1, MLLT3-KMT2A, and DEK-NUP214) and mutant genes (NPM1, CEBPA, RUNX1, FLT3, TP53, KIT, and ASXL1) were detected before treatment [8,21]. Samples from patients with mutant NPM1, PML-RARA, CBFB-MYH11, and RUNX1-RUNX1T1 mutations were subjected to PCR for MRD detection. MRD was defined based on previous reports [1,14]
Statistics

The 2-tailed Student’s t-test was used to evaluate the difference in CD25 expression between the two different subgroups. A Receiver Operating Characteristic (ROC) Curve was used to set the CD25 MFIR cut-off value. All the statistical analyses were performed by using the GraphPad Prism 6 (GraphPad Software, San Diego, CA). The MFIR values are presented as the means ± standard errors of the mean (SEM).

RESULTS

The expression of CD25

Firstly, we set up the CD25 MFIR cut-off value (5.46) by using the ROC curve.

[Additional file 2] Of the MRD-positive AML patients, 38.27% (31/81) were positive for CD25. Of the 75 specimens positive for CD25, approximately 58.68% (0.05% to 100%) of the MRD cells were positive for CD25. Compared to the MRD-negative samples (1.73 ± 0.09), the MRD-positive samples had a significantly increased MFIR (23.22 ± 1.45, p<0.05). [Table 1, Figures1, 2, and Additional file 3] The sensitivity of CD25 for detecting MRD was 5/10,000.[Figure 3]

The stability of CD25 in MRD-positive AML

The stability of CD25 was dynamically monitored in 127 BM specimens from 40 MRD-positive patients. Among these specimens, the CD25 MFIR of 7 MRD-positive samples varied between normal and abnormal ranges [Figure 2 and Additional file 4]. The CD25 MFIR of the other patients remained stable in either the abnormal range or the normal range.

Clinical characteristics

AML patients were stratified into three risk categories based on genetic information before treatment[1,8,21]. Of the CD25-positive patients with MRD, 65% and 35%
were in the intermediate and poor risk subgroups, respectively. Of the CD25-negative patients with MRD, 24%, 46% and 30% cases were in the favorable, intermediate and poor risk subgroups, respectively. Clinical information for all patients is listed in Table 1.

**Other characteristics of CD25-positive cases with MRD**

Of 31 MRD-positive AML patients expressing CD25, 6/31 cases were positive for concurrent FLT3-ITD and NPM1 mutations, another 6/31 exhibited FLT3-ITD and 3/31 exhibited NPM1 mutations. Additional genetic abnormalities of CD25-positive and CD25-negative patients with MRD are shown in Table 2.

We also observed the expressions of CD38 in 10 patients with MRD that were positive for CD25. Five patients were concurrently positive for CD34 and CD38, while three cases were positive for CD34 and negative for CD38, which is the immunophenotype of LSCs [22, 23]. One patient was negative for CD34 and positive for CD38.

**DISCUSSION**

Previous reports on CD25 expression in AML have been focused on its prognostic value. In this research, we identify the value of CD25 as a novel MRD marker in AML.

We initially observed that the expression of CD25 in normal myeloblasts from MRD-negative cases was quite low. This finding suggested that CD25 is a potential marker for MRD in AML. Then, we set up the upper cut-off value for the CD25 MFIR by using a ROC curve and separated the MRD-positive AML samples into two subgroups. Approximately 38% of the MRD-positive AML patients were positive for CD25. Based on other reports, CD25 is expressed in 10%-20% of AML patients
and the numbers of cases are much larger in these studies. Therefore, the bias toward the higher positive percentage of CD25 in our study may be caused by the small sample size. After comparing the CD25 MFIR between CD25-positive patients with MRD and those without MRD, we found that the difference was obvious. This result shows that high expression of CD25 is a reliable marker for MRD in AML.

We also compared the stability of CD25 in 127 BM specimens from 40 MRD-positive patients. The stability of CD25 varied between the normal and abnormal ranges in approximately 7 patients. This pattern means that the expression of CD25 could change at different time points. Therefore, it would be better to detect CD25 whenever MRD monitoring is performed.

In addition, we tried to determine the characteristics of CD25-positive patients with MRD. Regarding the genetic abnormalities, we obtained a similar conclusion as other reports [17]. FLT3-ITD and NPM1 mutations were the most common genetic aberrancies in AML patients positive for CD25. CD25 is highly expressed in LSCs [24]. In addition, CD25-positive AML blasts express an LSC-like gene profile [17]. Generally, the combination of CD34+ and CD38- is the recognized immunophenotype of LSCs in AML [22,23]. However, based on our result, not all CD25 positive MRD clusters are negative for CD38. This finding might indicate that CD25 can be expressed in AML cells other than LSCs. However, in this study, we only used four-parameter flow cytometry.

Our group is not the first to use CD25 as an MRD detection marker in AML. A Japanese group detected the expression of CD25 in AML patients before allogeneic hematopoietic stem cell transplantation and found out that AML patients with CD25-positive MRD at the time of transplantation had poor prognoses [25].
To our knowledge, our group is the first to describe the application of CD25 for MRD detection in detail. In the future, we will include more cases and use multiple-parameter flow cytometry.

CONCLUSION

CD25 is a promising marker for MRD in patients with AML.

LIST OF ABBREVIATIONS

FC, flow cytometry
BM, bone marrow
AML, acute myeloid leukemia
MRD, minimal residual disease
MFIR, mean fluorescence index ratio
LAIPs, leukemia-associated immunophenotypes
DfN, different from normal
LSCs, leukemic stem cells
mAbs, monoclonal antibodies
ROC, Receiver Operating Characteristic
SEM, standard errors of the mean

DECLARATIONS

Ethics approval and consent to participate

The study has been approved by the Ethical Committee of the Peking University International Hospital (C2017-005) and has been performed in accordance with the ethical standards as described in the 1964 Declaration of
Helsinki and its later amendments or comparable ethical standards. All patients were provided with informed written consent regarding the data collection and publication.

**Consent to publish**

We obtained written permission from all patients in the study to publish the manuscript reporting individual patient data.

**Availability of data and materials**

All data are presented in the manuscript and supplementary data.

**Competing interests**

None of the authors have any competing interests in regard to the manuscript.

**Funding**

This research did not receive any specific grant from funding agencies in public, commercial, or not-for-profit sectors.

**Authors’ contributions**

WW planned the entire research study, performed the flow cytometry experiments, and prepared the manuscript. YL performed the flow cytometry experiments and statistic analysis. LM collected patients information, and performed the statistic analysis. WQH collected patient samples, analyzed and interpreted the results. BJ supervised the entire study and revised the manuscript. All authors have read and approved the final manuscript.

**Acknowledgments**

We would like to thank all the patients. We also would like to thank Hui-Lin Shi, Bo-Yan Liu, Min Ou-Yang, Mei-Xiang Zhang, Lin Shi, and Jian-Xin Liu for their help.

**References**
1. Ravandi F, Walter RB, Freeman SD: Evaluating measurable residual disease in acute myeloid leukemia. Blood Adv. 2018, 2:1356-66.

2. Buccisano F, Maurillo L, Gattei V, Del Poeta G, Del Principe MI, Cox MC, Panetta P et al: The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia. 2006, 20:1783-9.

3. Chen X, Xie H, Wood BL, Walter RB, Pagel JM, Becker PS, Sandhu VK et al: Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol. 2015, 33:1258-64.

4. Grimwade D, Freeman SD: Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? Hematology Am Soc Hematol Educ Program 2014. 2014:222-33.

5. Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, Patel Y et al: Group UKNCRIAW: Assessment of Minimal Residual Disease in Standard-Risk AML. N Engl J Med. 2016, 374:422-33.

6. Ossenkoppele G, Schuurhuis GJ: MRD in AML: time for redefinition of CR? Blood. 2013, 121:2166-8.

7. Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, Erpelinck-Verschueren CAJ et al: Molecular Minimal Residual Disease in Acute Myeloid Leukemia. N Engl J Med. 2018, 378:1189-99.

8. Network NCC: NCCN Guidelines: acute myeloid leukemia, verison 3, 2019.

9. Othus M, Wood BL, Stirewalt DL, Estey EH, Petersdorf SH, Appelbaum FR, Erba HP et al: Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia. Leukemia. 2016, 30:2080-3.
10. Ossenkoppele G, Schuurhuis GJ: MRD in AML: does it already guide therapy decision-making? Hematology Am Soc Hematol Educ Program 2016. 2016:356-65.

11. Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T: The role of multiparameter flow cytometry for disease monitoring in AML. Best Pract Res Clin Haematol. 2010, 23:379-90.

12. San Miguel JF, Martinez A, Macedo A, Vidriales MB, Lopez-Berges C, Gonzalez M, Caballero D et al: Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood. 1997, 90:2465-70.

13. Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T, Maertens J et al: High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013, 31:3889-97.

14. Schuurhuis GJ, Heuser M, Freeman S, Bene MC, Buccisano F, Cloos J, Grimwade D et al: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018, 131:1275-91.

15. Kageyama Y, Miwa H, Arakawa R, Tawara I, Ohishi K, Masuya M, Nakase K et al: Expression of CD25 fluctuates in the leukemia-initiating cell population of CD25-positive AML. PLoS One. 2018, 13:e0209295.

16. Gonen M, Sun Z, Figueroa ME, Patel JP, Abdel-Wahab O, Racevskis J, Ketterling RP et al: CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood. 2012, 120:2297-306.

17. Cerny J, Yu H, Ramanathan M, Raffel GD, Walsh WV, Fortier N, Shanahan L et
al: Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML). Br J Haematol. 2013, 160:262-6.

18. Fujiwara SI, Muroi K, Yamamoto C, Hatano K, Okazuka K, Sato K, Oh I et al: CD25 as an adverse prognostic factor in elderly patients with acute myeloid leukemia. Hematology. 2017, 22:347-53.

19. Liu P, Jiang H, Che M, Fu R, Wang H, Li L, Zhang W et al: Abnormal CD25 expression on hematopoietic cells in myelodysplastic syndromes. Leuk Res. 2018, 67:12-6.

20. Wang W, Gao L, Li Y, Li ZL, Gong M, Huang FZ, Chen YR et al: The application of CD73 in minimal residual disease monitoring using flow cytometry in B-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2016, 57:1174-81.

21. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H et al: Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017, 129:424-47.

22. Hope KJ, Jin L, Dick JE: Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004, 5:738-43.

23. Jordan CT, Guzman ML: Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene. 2004, 23:7178-87.

24. Saito Y, Kitamura H, Hijikata A, Tomizawa-Murasawa M, Tanaka S, Takagi S, Uchida N et al: Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med. 2010, 2:17ra9.

25. Ikegawa S, Doki N, Kurosawa S, Yamaguchi T, Sakaguchi M, Harada K, Yamamoto K et al: CD25 expression on residual leukemic blasts at the time of
allogeneic hematopoietic stem cell transplant predicts relapse in patients with acute myeloid leukemia without complete remission. Leuk Lymphoma. 2016, 57:1375-81.

Tables

Table 1. Clinical information and laboratory results of AML patients after treatment

| CD25+MRD positive | CD25-MRD positive | MRD negative |
|--------------------|------------------|-------------|
| Patient number     | 31               | 50          | 36          |
| BM number          | 75               | 87          | 58          |
| Age                | 54 (19-77)       | 45 (18-81)  | 48 (18-82)  |
| Sex (male/female)  | 17/14            | 29/21       | 22/14       |
| Risk stratification of genetics | | | |
| Favorable          | 20               | 12          | Not recorded |
| Intermediate       | 11               | 23          | Not recorded |
| Adverse            | 11               | 15          | Not recorded |
| MRD blasts/ BM nucleated cells (%) (mean ± SEM) | 25.65 ± 3.35 | 14.83 ± 2.21 | None |
| CD25 MFIR (mean ± SEM) | 23.22 ± 1.45 b | 1.59 ± 0.07 c | 1.73 ± 0.09 d |

AML: acute myeloid leukemia
MRD: minimal residual disease
BM: bone marrow

a: There were 98 patients in total. Among the patients, 43 were assessed at multiple time points. Some of these samples may be distributed in different subgroups.
b: The MFIR of CD25 in CD25 positive AML cells
c: The MFIR of CD25 in all AML cells
d: The MFIR of CD25 in normal myeloblasts

Table 2. Genetic information of MRD-positive AML patients

| Genetic abnormalities   | CD25+MRD-positive | CD25-MRD-positive |
|-------------------------|------------------|------------------|
| PML-RARa                | 0                | 1                |
| RUNX1-RUNX1T1           | 1                | 6                |
| BCR-ABL1                | 2                | 0                |
| MLLT3-KMT2A             | 3                | 6                |
| NPM1 mutationa          | 9                | 9                |
| Biallelic mutated CEBPA | 0                | 2                |
| RUNX1 mutation          | 1                | 6                |
| FLT3-ITD                | 12               | 6                |
| TP53 mutation           | 0                | 2                |
| KIT mutation            | 1                | 1                |
| ASXL1 mutation          | 1                | 3                |

MRD: minimal residual disease
Six patients in the CD25-positive subgroup and 3 cases in the CD25-negative subgroup had concurrent *NPM1* mutation and *FLT3-ITD*.

In addition, other genetic abnormalities were observed in some patients.

Additional File Legends

**Additional file 1.** The minimal residual disease detection panels in acute myeloid leukemia.

**Additional file 2.** Receiver Operating Characteristic (ROC) Curve of CD25 MFIR.
Cut off < 5.457. Sensitivity is 100% (93.84% to 100%); specificity is 46.3% (38.44% to 54.29%); area is 0.6887 (p<0.001).

**Additional file 3.** Laboratory data of CD25 positive and MRD positive AML patients

**Additional file 4.** The variability of CD25 MFIR in MRD positive AML patients

Figures
Figure 1

Expression of CD25 in AML patients after treatment. The results of flow cytometry are shown. Seventy-five specimens from MRD-positive patients were positive for CD25. MRD: minimal residual disease; MFIR: mean fluorescence intensity ratio; AML: acute myeloid leukemia.

Figure 2

The expression profile of CD25 in blasts. From the first to the fourth figure shows...
Figure 3

The sensitivity of CD25 in MRD detection. The detection sensitivity of CD25 positivity in the MRD cluster was 5/10,000 relative to all bone marrow nucleated cells. MRD: minimal residual disease.

Figure 4

The stability of CD25 in the MRD cluster. The figure shows the dynamic variation in CD25 expression in the MRD cluster.

Supplementary Files
This is a list of supplementary files associated with the primary manuscript. Click to download.

Additional File 2.pdf
Additional File 4.docx
Additional File 1.docx
Additional File 3.docx